Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Diagnostic Microbiology and Infectious Disease|August 1, 2006
Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America)Jeffrey T Kirby, Thomas R Fritsche, Ronald N JonesThe Annals of Pharmacotherapy|December 31, 2002
CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy Alliance for Neutropenics and the Control of Emerging ResistanceAlan H Mutnick, Jeffrey T Kirby, Ronald N Jones, et al.Diagnostic Microbiology and Infectious Disease|July 13, 2004
In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infectionsThomas R Fritsche, Jeffrey T Kirby, Ronald N JonesDiagnostic Microbiology and Infectious Disease|March 11, 2008
Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillanceRonald N Jones, Jeffrey T Kirby, Paul R RhombergDiagnostic Microbiology and Infectious Disease|July 31, 2007
Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006)Paul R Rhomberg, Lalitagauri M Deshpande, Jeffrey T Kirby, et al.Journal of Clinical Microbiology|April 24, 2009
Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007)Shawn A Messer, Gary J Moet, Jeffrey T Kirby, et al.Journal of Clinical Microbiology|January 13, 2004
Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001)Jeffrey T Kirby, Helio S Sader, Timothy R Walsh, et al.Diagnostic Microbiology and Infectious Disease|March 23, 2007
Development of anidulafungin for disk diffusion susceptibility testing against Candida sppRonald N Jones, Jeffrey T Kirby, Shawn A Messer, et al.Journal of Clinical Microbiology|June 11, 2010
Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008)Shawn A Messer, Ronald N Jones, Gary J Moet, et al.The Journal of Antimicrobial Chemotherapy|November 27, 2004
Initial results from a longitudinal international surveillance programme for anidulafungin (2003)Shawn A Messer, Jeffrey T Kirby, Helio S Sader, et al.Pageof 2